Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) is considered the procedure of choice in patients with ulcerative colitis (UC) refractory to medical therapy. The incidence of pouchitis is 40% at 5 years. Ten to 15% of patients with pouchitis experience chronic pouchitis.
SUMMARY Background
Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) is considered the procedure of choice in patients with ulcerative colitis (UC) refractory to medical therapy. The incidence of pouchitis is 40% at 5 years. Ten to 15% of patients with pouchitis experience chronic pouchitis.
Aim
To determine the efficacy of medical therapies for the treatment of chronic refractory pouchitis in patients undergoing IPAA for UC.
Methods
A systematic computer-assisted search of the on-line bibliographic database MEDLINE and EMBASE was performed between 1966 and February 2016. All original studies reporting remission rates following medical treatment for chronic pouchitis were included. All study designs were considered. Remission was defined according to the individual study. Remission endpoints ranged from 15 days to 10 weeks. Chronic pouchitis was defined by each study.
Results
Twenty-one papers were considered eligible. Results from all studies combined suggested that overall remission was obtained in 59% of patients (95% CI: 44-73%). Antibiotics significantly induced remission in patients with chronic pouchitis with 74% remission rate (95% CI:56-93%), (P < 0.001). Biologics significantly induced remission in patients with chronic pouchitis with 53% remission rate (95% CI:30-76%), (P < 0.001). Steroids, bismuth, elemental diet and tacrolimus all can induce remission but failed to achieve significance. Faecal microbiota transplantation in a single study was not found to achieve remission.
Conclusions
Treatment of chronic refractory pouchitis remains difficult and is largely empirical. Larger randomised controlled trials will help aid the management of chronic pouchitis.
INTRODUCTION
Restorative proctocolectomy (RPC) with ileal pouch anal anastomosis (IPAA) is considered the procedure of choice in patients with ulcerative colitis (UC) refractory to medical therapy. 1 The incidence of acute pouchitis is 20% at 1 year and up to 40% at 5 years. 2 Pouchitis is clinically characterised by variable symptoms including increased stool frequency and fluidity, haematochezia, abdominal cramping, urgency and tenesmus, incontinence, fever and extraintestinal manifestations. 1 The first-line treatment of acute pouchitis is largely empirical with antibiotics. Ciprofloxacin and metronidazole are the most commonly used, often generating a rapid dramatic response. [3] [4] [5] [6] Chronic pouchitis develops in approximately 10-15% of patients with acute pouchitis and can be 'treatment responsive' or 'treatment refractory' to antibiotic therapy. 7, 8 Chronic pouchitis has been poorly defined, but in this review, patients will be considered to have chronic pouchitis if symptoms persist beyond 4 weeks of treatment.
A systematic review with meta-analysis in 2010 reviewed the efficacy of antibiotics and probiotics in pouchitis. 9 A systematic review in 2015 explored the use of biologics in pouchitis. 10 A further meta-analysis in 2014
reviewed the role of probiotics with the focus on maintainance of remission. 11 A Cochrane review in 2015 appraised two randomised controlled trials in the treatment and prevention of chronic refractory pouchitis. 12 This systematic review with meta-analysis builds on these reviews, adding information from all studies that treated chronic refractory pouchitis. Using medical databases and other sources, we reviewed the latest evidence in treating chronic refractory pouchitis. In addition to antibiotics, there is evidence that steroids, immunomodulators and biologics all have a role in treating chronic pouchitis.
OBJECTIVES
To determine the efficacy of oral and topical medical therapies including antibiotics, probiotics, immunomodulators, steroids and biologics for the treatment of chronic refractory pouchitis in patients who have undergone IPAA for UC.
METHODS
Types of studies Randomised controlled trials, cohort studies, observational studies and case reports were considered. Studies which reported duplicate results were excluded. Those where data could not be extracted were also excluded.
Types of participants
Adults patients (age ≥18 years) with chronic refractory pouchitis were included. Chronic refractory pouchitis was defined by each study. For this analysis, we used each study's definition of chronic refractory pouchitis for the systematic review.
Types of outcome measures
The primary outcome was the proportion of patients with clinical improvement or remission of pouchitis. The definition of clinical improvement or remission varied from study to study, meaning that it was difficult to make comparisons across studies. The definitions of clinical improvement or remission used in each study were used for extraction of the data.
Search methods for identification of studies
A computer-assisted search of the on-line bibliographic database MEDLINE and EMBASE was carried between 1966 and February 2016 by two independent researchers (JPS and NSD). The following medical Subject Heading (MeSH) terms were used which included both the root term and text words. Synonyms and word variations were combined using the "OR" function and then combined with other key terms using the "AND" function: "refractory" "chronic", "long term", "difficult", "unmanageable", "ulcerative colitis", "UC", "colitis", "ileum", "ileostomy", "postoperative complications", "pouchitis", "colonic pouches", "pouch", "proctocolectomy", "restorative", "colitis", "IPAA", "RPC", "j-pouch", "s-pouch", "w-pouch", "treatment", "management", "medication", "therapy", "therapeutics", "anti-TNF", "antibiotics", "steroids", "tumour necrosis factor-alpha", "remission", "spontaneous", "remission induction", "resolution", "cure". Manual searches of the reference list from the potentially relevant studies were performed in order to identify additional studies that may have been missed using the computer-assisted search strategy. Abstracts from conferences from the American Gastroenterological Association, American Society of Colon and Rectal Surgery, European Crohn's and Colitis, United European Gastroenterology and the British Society of Gastroenterology were also manually searched from 1965 to 2016 in order to identify unpublished studies.
Data collection and analysis
Study selection. Potentially relevant articles were reviewed in an independent fashion by two authors (JPS and NSD) to determine whether they met the inclusion criteria. The studies were then labelled as eligible, ineligible, or having insufficient information to make a judgement as to eligibility (which were then excluded). Any discrepancies were addressed by a joint re-evaluation of the original article.
Data collection. Eligible articles were reviewed by JPS and NSD and the results from the included articles were extracted into tables. The proportions of patients who had clinical improvement or entered remission were derived from each study (Tables 1 and  2 ).
Risk of bias. Two authors (JPS and NSD) independently assessed the methodologies using the Cochrane risk of bias tool for randomised controlled trials as described in the Cochrane handbook for systematic reviews of interventions. 13 Statistical analysis. For analysis the outcome of remission was considered as a binary outcome (yes/no). Metaanalysis methods were used to pool the percentage of patients in remission from the various studies. The analysis was implemented using the 'metaan' package with STATA (StataCorp LP, Texas, USA). For each study, the standard error of the proportion in remission was calculated using the normal approximation to the binomial distribution. For studies where the outcome was not observed in any patients, or in all patients (i.e. a 0% or 100% remission occurrence), the standard error was approximated by half the width of 95% confidence calculated using the exact binomial method.
The heterogeneity between studies was assessed based on the significance of the between-study heterogeneity, and also on the size of the I 2 value. Substantial heterogeneity was assumed if the I 2 value was above 50%. If there was substantial heterogeneity between studies, studies were pooled using the DerSimonian-Laird randomeffects method. A random-effects model was also used if there was no heterogeneity between studies. The analyses were performed for all studies combined, and then separately for each type of medication.
RESULTS

Description of studies
The literature search identified a total of 2954 studies. After removing duplicates 2587 studies remained for review of title and abstracts for eligibility. Two authors (JPS and NJD) independently reviewed the titles and abstracts of these studies. After screening abstracts 45 articles were reviewed in full. After screening individual papers 16 were included in the study. Five additional papers were included after manual reference searching. A total of 21 papers were considered eligible. Chronic refractory pouchitis was defined within each study. Sixteen out of 21 (76%) defined chronic pouchitis as greater than 4 weeks of symptoms despite having used antibiotics or alternative standard therapies. Three studies defined chronic pouchitis as requiring continuous antibiotics. In two studies we did not categorise the definition of chronic pouchitis.
EFFECTS OF INTERVENTIONS
Pouchitis defined as symptoms greater than 4 weeks following treatment with antibiotics or steroids Antibiotics. Gionchetti et al., 4 conducted a cohort study of 18 patients with chronic pouchitis who were treated orally with rifaximin 1 g b.d. and ciprofloxacin 500 mg b.d. for 15 days. Pouchitis was defined as a pouch disease activity index (PDAI) ≥7. Chronic pouchitis was defined as no response after treatment with antibiotics (such as metronidazole, or ciprofloxacin or amoxycillin/ clavulanic acid) for at least 4 weeks. Six of 18 (33%) patients went into remission and 10/18 (56%) improved after 15 days. The median PDAI scores before and after therapy were 11 (range 9-17) and 4 (range 0-16) respectively (P < 0.002). No adverse events were reported. Abdelrazek et al. 15 conducted a cohort study on eight patients with chronic pouchitis who were treated with 2 weeks of rifaximin 1 g b.d. and ciprofloxacin 500 mg b.d. Pouchitis was defined using the PDAI. Chronic pouchitis was defined as no response to at least 4 weeks of standard antibiotic therapy or relapse immediately when antibiotic treatment was stopped or reduced. Remission was defined as an improvement of three points on the PDAI. Seven of the eight (88%) patients either went into remission (n = 5) or improved (n = 2). The median (range) PDAI scores before and after therapy were 12 4, 9-17 and 0 (0-15), respectively, (P = 0.018). There were no significant side effects reported. (1 g/day) were used as controls. All patients had a PDAI ≥7 at entry. Chronic refractory pouchitis was defined as symptoms for more than 4 weeks with endoscopic and histological inflammation despite treatment with single or dual antibiotics for more than 4 weeks. In the antibiotic group, 87.5% of patients achieved clinical remission and 88% achieved clinical response, compared to 50% in the mesalazine group for remission and 50% for response. This was, however, not statistically significant (P = 0.069). In the antibiotic group, two patients had adverse events (peripheral neuropathy and dysgeusia) but continued treatment.
Steroids. Gionchetti et al. 17 conducted an open-label non-randomised study in 20 consecutive patients with chronic pouchitis who were treated with budesonide controlled ileal release 9 mg/day for 8 weeks. Chronic pouchitis was defined as a total PDAI score of ≥7, and not responsive to antibiotics for 4 weeks. Remission was defined as a combination of PDAI of ≤2, endoscopic score ≤1 and total PDAI score ≤4. Fifteen of 20 patients (75%) achieved remission. The median total PDAI scores before and after therapy were, respectively, 14 (range 9-16) and 3 (range 2-10) (P < 0.001).
Gionchetti et al., 18 conducted an open-label nonrandomised study in 10 consecutive patients with chronic pouchitis who were treated with beclomethasone 10 mg/ day for 8 weeks. Current active refractory pouchitis was defined as a PDAI score of ≥7 and no response to at least 4 weeks of standard antibiotic treatment (ciprofloxacin 1 g once a day or metronidazole 1 g once a day). Remission was defined as a combination of PDAI clinical score of ≤2, endoscopic score of ≤1 and a total PDAI score of ≤4. Eight of the 10 (80%) treated patients achieved remission, while two had only a mild improvement. The median bowel frequency decreased significantly from 10 (range 7-15) to 6 (range 3-11) after steroid treatment (P < 0.001).
Enemas. Tremaine et al., 19 conducted a randomised, double-blind placebo controlled trial in 40 patients with chronic pouchitis who were randomly assigned either 270 mg bismuth enema (n = 20) or placebo (n = 20). Chronic pouchitis was defined as continuous symptoms of pouchitis for more than 4 weeks and a PDAI score ≥7. Patients had either failed or were intolerant to metronidazole as well as other commonly used treatments for pouchitis. Remission was defined as a reduction in the PDAI by at least three points at 3 weeks. There were no significant differences between the populations at baseline. At week 3, 9/20 (45%) of patients in both the bismuth and placebo groups had improved. No patient achieved remission in either group. There was no significant difference in response to therapy in the treatment or the placebo with regard to remission. One patient in the bismuth group reported a worsening of diarrhoea requiring hospital admission.
Gionchetti et al. 20 conducted an open-label nonrandomised study in twelve patients with chronic pouchitis who were administered bismuth carbomer enema at night for 45 days. Chronic pouchitis was defined as continuous symptoms for more than 4 weeks and the need for antibiotics or steroids for more than 15 days per month to control symptoms. Clinical remission was defined as a decrease in PDAI ≥2. Ten of 12 treated patients (83%) went into remission after 45 days. No serious side effects were reported. Milner et al., 21 conducted an open-label, uncontrolled study in 12 patients with chronic pouchitis who were treated with 240 mg alicaforsen antisense enema nightly for 6 weeks. Patients underwent 2 weeks of washout prior to enrolment. Chronic refractory pouchitis was defined as patients who had symptoms for greater than 4 weeks and had failed alternative therapies, with a PDAI score of ≥7. The primary endpoint was a reduction in PDAI from baseline at week 6. At week 6, 7/12 (58%) of patients were in remission with PDAI <7. The mean decrease in PDAI from baseline was six points. No drug related serious or significant adverse effects were reported during the study. Uchino et al., 22 conducted a nonrandomised openlabel study in 10 patients with chronic refractory pouchitis who were treated with once daily tacrolimus enema (0.08 mg/kg) in the morning for 8 weeks. Chronic pouchitis was defined by no response to a 4 week course of a single antibiotic (metronidazole or ciprofloxacin) and requiring therapy of for at least 4 weeks of dual antibiotics. A PDAI ≥7 was used as confirmation of the diagnosis. Clinical remission and clinical response were defined a clinical sub-score of zero points and a clinical sub-score decrease of more than three points. Seven of the 10 patients achieved complete remission of clinical symptoms, and a total of nine patients were clinical responders. The mean PDAI score decreased significantly to 7.8 AE 0.8 points (range, 6-15) after 8 weeks (P < 0.01). Three patients reported feeling mild burning in the pouch, which was not sufficient to warrant discontinuation of the 8-week application.
Biologics. Ferrante et al., 23 conducted a retrospective study in 11 patients with chronic refractory pouchitis who were treated with standard infusions of infliximab (5 mg/kg body weight). Chronic refractory pouchitis was defined as symptom duration greater than 4 weeks following standard treatment. A complete clinical response was defined as cessation of diarrhoea, urgency, incontinence, blood loss and abdominal pain. A partial clinical response was defined as a marked clinical improvement, but persisting symptoms. All other outcomes were defined as no short-term clinical response. Long-term response was evaluated at last follow-up. Short-term response to infliximab was evaluated at week 10. At week 10, 1/11 (9%) out-patients did not show any clinical benefit and needed a permanent ileostomy, 7/11 (64%) patients had a partial clinical response, and 3/11 (27%) had a full clinical response. The modified PDAI (mPDAI) dropped significantly from 9 to 5 (P = 0.011). In the subgroup of 10 patients with chronic refractory pouchitis in the absence of pouch fistula or pre-pouch ileitis who initially responded to infliximab, seven were still on infliximab after a median follow-up of 8.5 (range 2-38) months. Two patients had to stop because of a delayed hypersensitivity reaction, while one patient could be bridged to azathioprine. The remaining seven patients underwent a new endoscopy at the end of follow-up. Four of them did not show any lesion, while three had clear endoscopic activity despite a sustained clinical benefit. Gionchetti et al., 24 conducted an open-label nonrandomised study in 19 patients with chronic pouchitis who were treated with either 5 mg/kg of infliximab at weeks 0, 2, 6 or adalimumab 160/80 mg at weeks 0 and 2, then 40 mg every other week. Chronic pouchitis was defined as unresponsive to a month of antibiotics or 2 months of budesonide. Remission was defined as a PDAI score of one. Short-term efficacy was measured at week 10. Twelve patients received infliximab and five adalimumab. Nine of 12 (75%) and 5/7 (71%) showed remission respectively in the infliximab and adalimumab group. The median PDAI scores before and after therapy were 13 (range 8-18) and 2 (range 0-9) in the infliximab group(P < 0.001), and 14 (range 9-18) and 2 (range 0-10) in the adalimumab group (P < 0.001). No serious side effects were registered. Viazis et al., 25 conducted an open prospective cohort study in seven patients with chronic refractory pouchitis who were treated with infliximab 5 mg/kg at 0, 2 and 6 weeks and then, every 2 months for a year. There were no significant adverse events reported.
Other treatments. Landy et al., 28 conducted a nonrandomised study in eight patients with chronic pouchitis who were given a 30 g fresh donor stool via a nasogastric tube on a single occasion. Chronic pouchitis was defined as patients with PDAI ≥7 who had not responded to standardised therapy. The outcome measure was remission at 4 weeks after FMT. At 4 weeks post-FMT, no patient achieved remission; however, two patients regained sensitivity to ciprofloxacin. No adverse events were reported.
McLaughlin et al. 29 conducted a non-randomised prospective study in seven patients who received 28 days of exclusive elemental diet enough to reach their daily energy requirements. Chronic pouchitis was defined as patients with a PDAI ≥7 who were unresponsive to 4 weeks of combined antibiotic treatment. Outcome was reduction in stool frequency at day 28 and reduction in PDAI. Treatment with elemental diet resulted in a significant reduction in stool frequency (from median 12 to 6, P = 0.028) and the PDAI symptom score (from 4 to 1, P = 0.039). There was a nonsignificant trend towards an improvement in the ability to defer defecation (from 25 to 60 min, P = 0.078). There were no adverse events reported.
Interventions when chronic pouchitis was defined as requiring continuous antibiotics Antibiotics. Mimura et al., 6 conducted a cohort study of 44 patients with chronic pouchitis who were treated using a combination of metronidazole 400 mg (UK population) or 500 mg (Italian population) twice daily and ciprofloxacin twice daily for 28 days. Chronic pouchitis was defined as a history of pouchitis at least twice in the last 12 months or persistent pouchitis requiring continual antibiotics and a PDAI ≥7. Thirty six of 44 patients (82%) achieved remission. One patient withdrew from the trial as they developed nausea and dysgeusia to metronidazole.
Biologics. Viscido et al., 30 conducted an open-label nonrandomised study in a subgroup of seven patients with chronic pouchitis who were treated with 5 mg/kg of infliximab at week 0, 2 and 6. Treatment after this was 'on demand' only. Patients also received 2.5 mg/kg of azathioprine at the time of the first infliximab infusion. Chronic refractory pouchitis was defined as persistent active pouchitis unresponsive to continuous antibiotics. Complete response was defined as improvement in wellbeing and cessation of diarrhoea, urgency/incontinence, stool blood, abdominal pain. A partial response was defined as an improvement or reduction of the symptoms. All other outcomes were defined as no response. Among the seven patients with pouchitis who received infliximab, six had a complete clinical response, and one patient had partial clinical response 10 weeks after the first infusion. At 6 month follow-up, one patient had developed a thoracic herpes simplex virus infection, which required treatment with acyclovir (4 g/day for 10 days), without withdrawal of immunosuppressive treatment. Iizuka et al., 31 reported a case of a 29-year woman with chronic pouchitis who was treated with infliximab at weeks 0, 2, 6 and then every 8 weeks up until a year. Chronic refractory pouchitis was defined as a PDAI of >10 after 2 years of antibiotic treatment. After 40 weeks of treatment, the patient's abdominal pain and clinical symptoms subsided and her PDAI was five. She continued treatment for a year and remained in remission.
Effects of interventions when chronic pouchitis definition cannot be categorised Antibiotics. Madden et al., 3 conducted a double-blind crossover trial in 13 patients with chronic pouchitis who were treated with metronidazole 400 mg or placebo.
Patients were randomised to receive either metronidazole 400 mg by mouth three times a day or placebo for 2 weeks. The drug was stopped for a wash out period. Remission was not defined but improvement in stool frequency was used an assessment of improvement. There were 11/13 subjects who completed the trial; one withdrew due to an episode of intestinal obstruction. Stool frequency improved in 8/11 (73%) receiving metronidazole, worsened in two and was unchanged in one. Placebo had no effect on stool frequency in the 11 patients who received treatment. Metronidazole improved stool frequency by four actions/day (P < 0.05, 95% CI). Six patients (55%) reported side effects while on metronidazole including an unpleasant taste (2), nausea (2), vomiting (1), abdominal discomfort (1), headache (1), skin rash (1).
Tacrolimus. Ng et al., 32 conducted a retrospective single centre review of all patients with inflammatory bowel disease that received tacrolimus 0.05 mg/kg twice daily orally. A sub group of patients with chronic pouchitis were included. Chronic pouchitis was defined as patients experiencing moderate to severe chronic active disease, were steroid dependent or had failed conventional therapy (azathioprine, mercaptopurine or infliximab). Clinical remission was defined as a modified PDAI <5 at week four of treatment. All patients received an initial dose of 0.1 mg/ kg/day in two divided doses then dose was adjusted to reach a trough level of 5-10 ng/mL. One patient with chronic pouchitis took part in the study and achieved remission with a reduction of mPDAI from 8 to 4 and a reduction of stool frequency from 25 to 12 times per day. There were no reported adverse events in this patient.
The pooled results for all studies, and for each medication separately, are summarised in the next table. These show the number of studies, and details of the heterogeneity both in terms of the significance and the I 2 value. The pooled results are also shown, and are the pooled percentage in remission, along with corresponding confidence intervals (Figures 1-3) . 
DISCUSSION
The results from all studies combined suggested that, overall, remission was obtained in 59% of patients (95% CI: 44-73%). There was considerable heterogeneity between the different studies, with statistically significant heterogeneity and a high I 2 value of 88%.
The results for different types of medication showed varying results, ranging from a 0% remission for FMT and up to a 77% remission for steroids. For most although not all types of medication, there was considerable heterogeneity between studies.
Antibiotics significantly induced remission in patients with chronic pouchitis with 70% remission rate (95% CI: 50-90%) (P < 0.001). Biologics significantly induced remission in patients with chronic pouchitis with 53% remission rate (95% CI: 30-76%), (P < 0.001). Bismuth significantly induced remission in patients with chronic pouchitis in 41% (95% CI: 0-100%), (P < 0.001) but had a large confidence interval suggesting that the true effect is not known. Steroids induced remission in 77% of patients (95% CI 62-92%) but failed to achieve significance (P = 0.75). Tacrolimus induced remission in 72% (95% CI 45-100%) but failed to achieve significance (P = 0.57). Alicaforsen and elemental diets had remission rates of 58% (95% CI 28-85%) and 71% (95% CI 29-96%) respectively but these were based on a single study. FMT failed to achieve remission in patients with chronic pouchitis with remission rates of 0% (95% CI: 0-37%) in a single study.
The treatment of chronic pouchitis with the aim of achieving remission remains a challenge. This likely reflects our limited knowledge on the pathogenesis of pouchitis. 33, 34 Pouchitis not only causes morbidity to the patient but is also associated with financial and economic burden. 35 Antibiotics, usually in combination such as metronidazole and ciprofloxacin are generally first-line therapy, with rifaximin and tinidazole being alternative agents to try in combination. Second-line treatment options include corticosteroids such as beclomethasone or budesonide. Biologics including infliximab and adalimumab are third line agents that can be used to treat chronic pouchitis. Less well-studied agents such as bismuth, tacrolimus and alicaforsen may be considered as alternatives to the above therapies. Studies presented in this review must be interpreted with caution due to the small number of trials, lack of randomised placebo controlled trials and small patient numbers. Only one of the studies was considered to be of moderate quality with the rest of the studies considered low or very low in quality. The lack of high quality head to head trials makes it difficult to measure the benefit of one drug or agent over another and it is not possible to draw conclusions about the comparative efficacy of each agent. Due to small sample populations, it is also difficult to draw conclusions about the tolerability of each agent.
In many trials, there is a lack of agreement on what defines chronic pouchitis and what defines remission. A consensus definition of chronic pouchitis with standardised outcome measures would help the analysis and interpretation of the true efficacy of each treatment. Many studies only reported short-term safety outcomes. It is also important to ensure that long-term safety data are available for each agent and this should be taken into account when designing future studies.
A clinical algorithm based on the evidence in this review and St Mark's experience is suggested for the treatment of chronic pouchitis (Figure 4 ).
CONCLUSION
The treatment of chronic pouchitis remains difficult and is largely empirical. Our knowledge of the treatment of this condition is based on small studies with often poor study designs. Studies are mostly single centred with small patient numbers which reflects a condition that is rare and that requires specialist treatment. There is also a paucity of data exploring the long-term safety of some treatment options available to patients with chronic pouchitis. To improve data, larger randomised controlled trials will be beneficial. To overcome some of the limitations addressed in this review, a multi-centre, multi-national approach is needed.
